噻唑烷二酮类药物与心血管风险：目前可得的证据会改变2型糖尿病的治疗策略吗？ - Suppr

Suppr

超能文献

Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?

作者信息

Vaccaro Olga, Riccardi Gabriele

出版信息

Nutr Metab Cardiovasc Dis. 2008 Feb;18(2):85-7. doi: 10.1016/j.numecd.2008.01.003. Epub 2008 Feb 15.

DOI:10.1016/j.numecd.2008.01.003

PMID:18280715

Abstract

摘要

相似文献

Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?

Nutr Metab Cardiovasc Dis. 2008 Feb;18(2):85-7. doi: 10.1016/j.numecd.2008.01.003. Epub 2008 Feb 15.

[Glitazone - mailing no 1. In response to DMW 49/2007].

Dtsch Med Wochenschr. 2008 Feb;133(6):261; author reply 262-3. doi: 10.1055/s-2008-1017508.

[Glitazone - mailing no 3. In response to DMW 49/2007].

Dtsch Med Wochenschr. 2008 Feb;133(6):261-2; author reply 262-3. doi: 10.1055/s-2008-1017510.

[Glitazones critically evaluated].

Dtsch Med Wochenschr. 2007 Dec;132(49):2619. doi: 10.1055/s-2007-993106.

[Too positive comment on glitazones].

Ugeskr Laeger. 2007 Feb 19;169(8):733; author reply 733.

[Rosiglitazone].

Ugeskr Laeger. 2010 Sep 20;172(38):2631; author reply 2631.

Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.

Harv Heart Lett. 2007 Aug;17(12):1-2.

Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.

J Am Coll Cardiol. 2010 Apr 27;55(17):1885-94. doi: 10.1016/j.jacc.2010.02.014.

[Rosiglitazone--statistics for benefits and problems].

Tidsskr Nor Laegeforen. 2007 Oct 18;127(20):2702-3.

Cardiovascular risk of rosiglitazone: another perspective.

J Pharm Pharmacol. 2008 Dec;60(12):1573-82. doi: 10.1211/jpp.60.12.0002.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?

Nutr Metab Cardiovasc Dis. 2008 Feb;18(2):85-7. doi: 10.1016/j.numecd.2008.01.003. Epub 2008 Feb 15.

[Glitazone - mailing no 1. In response to DMW 49/2007].

Dtsch Med Wochenschr. 2008 Feb;133(6):261; author reply 262-3. doi: 10.1055/s-2008-1017508.

[Glitazone - mailing no 3. In response to DMW 49/2007].

Dtsch Med Wochenschr. 2008 Feb;133(6):261-2; author reply 262-3. doi: 10.1055/s-2008-1017510.

[Glitazones critically evaluated].

Dtsch Med Wochenschr. 2007 Dec;132(49):2619. doi: 10.1055/s-2007-993106.

[Too positive comment on glitazones].

Ugeskr Laeger. 2007 Feb 19;169(8):733; author reply 733.

[Rosiglitazone].

Ugeskr Laeger. 2010 Sep 20;172(38):2631; author reply 2631.

Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.

Harv Heart Lett. 2007 Aug;17(12):1-2.

Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.

J Am Coll Cardiol. 2010 Apr 27;55(17):1885-94. doi: 10.1016/j.jacc.2010.02.014.

[Rosiglitazone--statistics for benefits and problems].

Tidsskr Nor Laegeforen. 2007 Oct 18;127(20):2702-3.

Cardiovascular risk of rosiglitazone: another perspective.

J Pharm Pharmacol. 2008 Dec;60(12):1573-82. doi: 10.1211/jpp.60.12.0002.